Abstract Library

#4294 Measuring quality of life in patients receiving radionuclide therapy using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ- C30) and Gastro-intestinal NET (GINET) 21

Introduction: Neuroendocrine tumours over express somatostatin receptors on the cell surface. These receptors can be targeted by radiation via Peptide Receptor Radionuclide Therapy (PRRT). NETTER 01 trial demonstrated excellent results in progression-free survival. Scottish National service commenced April 2019 at Beatson West of Scotland Cancer Centre. Service Level Agreement to submit multiple metrics including Patient Reported Outcome Measures (PROM) and Patient Reported Experience Measures (PREM). EORTC QLQ 30 and GI NET 21 validated research tools which are used to measure outcomes.

Conference:

Presenting Author: Wotherspoon I

Authors: Wotherspoon I,

Keywords: EORTC 30 QLQ with the GINET 21 module,

#3858 OTP, CD44, and Ki-67 – A prognostic marker panel for relapse free survival in patients with surgically resected pulmonary carcinoid

Introduction: Relapse occurs in 10% of patients with resected pulmonary carcinoid (PC). While typical carcinoids (TC) show low relapse rates, safe exclusion from long-term follow-up (FU) is impossible partly due to high interobserver variation in the WHO classification.

Conference:

Presenting Author: Moonen L

Authors: Moonen L, Derks J, den Bakker M, Hillen L, von der Thüsen J,

Keywords: Pulmonary Carcinoid, OTP, CD44, Ki-67, biomarker, prognosis,

#3464 Digital quantification of somatostatin receptor subtype 2 immunostaining in pancreatic neuroendocrine tumors and GH-secreting adenoma: A validation study

Introduction: Somatostatin receptor subtype 2 (SST2) immunostaining (IHC) is routinely performed in neuroendocrine tumors (NET) and recommended in acromegaly guidelines. No univocal score of SST2 IHC has been validated yet.

Conference:

Presenting Author: Campana C

Authors: Campana C, van Koetsveld P, Iyer A, van Velthuysen M, van den Dungen E,

Keywords: SST2, digital image analysis, panNET, staining intensity, percentage of positive cell,

#3404 Defining disease status in gastroenteropancreatic neuroendocrine tumors: Choi criteria or RECIST?

Introduction: Adequate monitoring of changes in tumor load is fundamental for the assessment of disease evolution and response to treatment. There is an ongoing debate on the utility of RECIST v1.1 in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Conference:

Presenting Author:

Authors: van Treijen M, Schoevers J, Heeres B, van der Zee D, Maas M,

Keywords: treatment response, GEP-NET, imaging, surveillance,

#3226 Immunohistochemical staining with neuroendocrine markers is essential in the diagnosis of neuroendocrine neoplasms of the esophagogastric junction

Introduction: Neuroendocrine neoplasms (NENs) of the esophagogastric junction (EGJ) are uncommon and the classification of these tumors has been revised several times. Since 2016, at the Department of Pathology, Rigshospitalet, Denmark, all adenocarcinomas (ACs) and poorly differentiated carcinomas of the EGJ have been stained routinely with the neuroendocrine markers, Synaptophysin and Chromogranin A, in order to detect a possible neuroendocrine component.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Jepsen D

Authors: Jepsen D, Fiehn A, Garbyal R, Engel U, Holm J,

Keywords: neuroendocrine neoplasm, neuroendocrine carcinoma, mixed neuroendocrine non-neuroendocrine neoplasm, esophagogastric junction, Synaptophysin, Chromogranin A,